{"createdAt":"8/2/2020, 1:17:48 PM","timestamp":1596388668943,"Company ID number":"115","DMX_ISSUER_NAME":"HUALAN BIOLOGICAL ENGINEERING, INC.","DMX_ISSUER_ID":"IID000000002169675","Country of Classification":"CHINA","name":"Hualan Biological Engineering Inc ","code":"002007","stock_exchange":"Shenzhen Stock Exchange","people":[{"id":"华兰生物工程股份有限公司_安康","group":"board","name":"安康","title":"董事长,董事","isMale":true,"age":"71","degree":"本科","salary":"94.00万","stockAmount":"3.257亿","description":"安康先生,中国国籍,1949年出生,毕业于河南师范大学生物系,大学文化,医学生物学高级工程师,河南省第六、七、八、九届政协委员,河南省第十届、十一届人大代表,第十二届全国人大代表,享受国务院政府特殊津贴。1974年参加工作,历任新乡市地区卫生防疫站科长、兰州生物制品研究所处长。曾先后获得全国科学大会奖、卫生部甲级成果奖、国家科技二等奖及省、市级科技奖,现任华兰生物工程股份有限公司董事长、总经理。","lastUpdated":"2019-04-27"},{"id":"华兰生物工程股份有限公司_范蓓","group":"board","name":"范蓓","title":"董事","isMale":false,"age":"48","degree":"硕士","salary":"70.00万","stockAmount":"225.2万","description":"范蓓女士,中国国籍,1972年出生,毕业于河南师范大学生物系,硕士研究生,医学生物学高级工程师。华兰生物工程股份有限公司总经理办公室主任、副总经理、董事会秘书。现任华兰生物工程股份有限公司董事、常务副总经理。","lastUpdated":"2019-04-27"},{"id":"华兰生物工程股份有限公司_王启平","group":"board","name":"王启平","title":"董事","isMale":true,"age":"66","degree":"本科","salary":"64.00万","stockAmount":"164.8万","description":"王启平先生,中国国籍,1954年出生,毕业于上海纺织大学会计专业,会计师。曾任新乡市生物化工厂副总会计师、公司财务部经理、财务总监。现任公司董事、副总经理、内审部经理。","lastUpdated":"2019-04-27"},{"id":"华兰生物工程股份有限公司_安颖","group":"board","name":"安颖","title":"董事","isMale":false,"age":"63","degree":"本科","salary":"0.00","stockAmount":"-","description":"安颖女士,中国国籍,1957年出生,大学文化,高级经济师,中共党员。1976年参加工作,曾任山西大同口泉中学教师、河南省新乡第一卫校教师;1993年至今在中国政法大学人事处工作,现任华兰生物工程股份有限公司董事。","lastUpdated":"2019-04-27"},{"id":"华兰生物工程股份有限公司_黄培堂","group":"board","name":"黄培堂","title":"独立董事","isMale":true,"age":"75","degree":"本科","salary":"4.000万","stockAmount":"-","description":"黄培堂,男,中国籍,毕业于中国科技大学。历任中国军事医学科学院微生物工程所所长,中国军事医学科学院副院长,现任北京金豪制药股份有限公司董事。","lastUpdated":"2019-04-27"},{"id":"华兰生物工程股份有限公司_王云龙","group":"board","name":"王云龙","title":"独立董事","isMale":true,"age":"58","degree":"","salary":"--","stockAmount":"-","description":"王云龙先生,中国国籍,1962年出生,教授,教授级高级工程师,河南省“五一劳动奖章”获得者,中原学者,全国优秀科技工作者,享受国务院政府特殊津贴。曾任南阳农业职业学院系主任,河南华美生物工程公司研究室主任、总工程师、技术总裁。现任河南省生物工程技术研究中心主任、首席科学家。","lastUpdated":"2020-04-16"},{"id":"华兰生物工程股份有限公司_刘万丽","group":"board","name":"刘万丽","title":"独立董事","isMale":false,"age":"39","degree":"博士","salary":"--","stockAmount":"-","description":"刘万丽女士,中国国籍,1981年出生,注册会计师。2011年6月毕业于厦门大学,会计学专业,获得博士学位,现任河南大学副教授。","lastUpdated":"2020-04-16"},{"id":"华兰生物工程股份有限公司_马超援","group":"supervisoryCommittee","name":"马超援","title":"监事会主席","isMale":true,"age":"36","degree":"本科","salary":"9.000万","stockAmount":"-","description":"马超援,男,1984年出生,中国国籍,2009年7月毕业于新乡医学院临床医学专业,获学士学位,2009年7月起在公司总经理办公室工作。","lastUpdated":"2019-04-29"},{"id":"华兰生物工程股份有限公司_蔡林林","group":"supervisoryCommittee","name":"蔡林林","title":"监事","isMale":true,"age":"34","degree":"本科","salary":"9.000万","stockAmount":"-","description":"蔡林林,男,1986年出生,中国国籍,2008年7月毕业于新乡医学院医学英语专业,获学士学位,2008年4月起在公司总经理办公室工作。","lastUpdated":"2019-04-27"},{"id":"华兰生物工程股份有限公司_王延朝","group":"supervisoryCommittee","name":"王延朝","title":"职工监事","isMale":true,"age":"31","degree":"本科","salary":"8.000万","stockAmount":"-","description":"王延朝先生,男,1989年出生,中国国籍,2011年7月毕业于河南师范大学人力资源管理专业,学士学位,2011年7月起在公司人力资源部工作,现任华兰生物工程股份有限公司人力资源部人事主管。","lastUpdated":"2019-04-29"},{"id":"华兰生物工程股份有限公司_安康","group":"manager","name":"安康","title":"总经理","isMale":true,"age":"71","degree":"本科","salary":"94.00万","stockAmount":"3.257亿","description":"安康先生,中国国籍,1949年出生,毕业于河南师范大学生物系,大学文化,医学生物学高级工程师,河南省第六、七、八、九届政协委员,河南省第十届、十一届人大代表,第十二届全国人大代表,享受国务院政府特殊津贴。1974年参加工作,历任新乡市地区卫生防疫站科长、兰州生物制品研究所处长。曾先后获得全国科学大会奖、卫生部甲级成果奖、国家科技二等奖及省、市级科技奖,现任华兰生物工程股份有限公司董事长、总经理。","lastUpdated":"2019-04-27"},{"id":"华兰生物工程股份有限公司_范蓓","group":"manager","name":"范蓓","title":"常务副总经理","isMale":false,"age":"48","degree":"硕士","salary":"70.00万","stockAmount":"225.2万","description":"范蓓女士,中国国籍,1972年出生,毕业于河南师范大学生物系,硕士研究生,医学生物学高级工程师。华兰生物工程股份有限公司总经理办公室主任、副总经理、董事会秘书。现任华兰生物工程股份有限公司董事、常务副总经理。","lastUpdated":"2019-04-27"},{"id":"华兰生物工程股份有限公司_谢军民","group":"manager","name":"谢军民","title":"董事会秘书,财务总监","isMale":true,"age":"53","degree":"本科","salary":"51.00万","stockAmount":"115.8万","description":"谢军民先生,中国国籍,1967年出生,毕业于山西财经大学会计系,大学文化,高级会计师,注册会计师。1992年7月至1997年12月,在郑州纺织工学院从事会计专业教学工作;1997年12月至2000年10月,任河南华为会计师事务所项目经理、高级经理;2000年10月至2002年3月,任北京天一会计师事务所河南分所副主任会计师;2002年3月至2006年11月,任北京中洲光华会计师事务所河南分所副主任会计师;2006年12月至2009年11月,任天健光华(北京)会计师事务所河南分所副主任会计师;2009年12月至2010年12月,任天健正信会计师事务所有限公司河南分所副主任会计师。2011年3月起任公司审计总监兼内审部经理,现任华兰生物工程股份有限公司财务总监、董事会秘书。","lastUpdated":"2016-04-28"},{"id":"华兰生物工程股份有限公司_王启平","group":"manager","name":"王启平","title":"副总经理","isMale":true,"age":"66","degree":"本科","salary":"64.00万","stockAmount":"164.8万","description":"王启平先生,中国国籍,1954年出生,毕业于上海纺织大学会计专业,会计师。曾任新乡市生物化工厂副总会计师、公司财务部经理、财务总监。现任公司董事、副总经理、内审部经理。","lastUpdated":"2019-04-27"},{"id":"华兰生物工程股份有限公司_潘若文","group":"manager","name":"潘若文","title":"副总经理","isMale":false,"age":"52","degree":"硕士","salary":"64.00万","stockAmount":"163.3万","description":"潘若文女士,中国国籍,1968年出生,毕业于华东理工大学生化系,硕士研究生,医学生物学高级工程师。曾任公司质保部经理、副总经理、华兰生物疫苗有限公司常务副总经理。现任公司副总经理、华兰生物疫苗有限公司总经理。","lastUpdated":"2016-04-28"},{"id":"华兰生物工程股份有限公司_张宝献","group":"manager","name":"张宝献","title":"副总经理","isMale":true,"age":"49","degree":"硕士","salary":"64.00万","stockAmount":"105.9万","description":"张宝献先生,中国国籍,1971年出生,毕业于河南师范大学生物系,硕士研究生,工程师。曾华兰生物工程股份有限公司生产部副经理、华兰生物工程(苏州)有限公司副总经理、公司监事等职。现任华兰生物工程股份有限公司副总经理、华兰生物工程重庆有限公司总经理。","lastUpdated":"2016-04-28"},{"id":"华兰生物工程股份有限公司_马小伟","group":"manager","name":"马小伟","title":"副总经理","isMale":true,"age":"52","degree":"本科","salary":"59.00万","stockAmount":"129.9万","description":"马小伟先生,中国国籍,1968年出生,毕业于河南农业大学,医学生物学高级工程师。曾担任公司生产总监、监事,现任公司副总经理。","lastUpdated":"2016-04-28"},{"id":"华兰生物工程股份有限公司_安文琪","group":"manager","name":"安文琪","title":"副总经理","isMale":false,"age":"41","degree":"博士","salary":"32.00万","stockAmount":"32.18万","description":"安文琪女士,中国国籍,1979年出生,2009年6月毕业于吉林大学生物化学与分子生物专业,博士研究生学历、高级管理人员工商管理硕士、高级工程师。华兰生物工程股份有限公司研发部副经理。现任华兰生物工程股份有限公司研发中心副主任、华兰生物疫苗有限公司副总经理、华兰基因工程有限公司总经理。","lastUpdated":"2018-03-27"}],"companyName":"华兰生物工程股份有限公司","province":"河南省","englishName":"Hualan Biological Engineering Inc","industry":"医药生物 — 生物制品Ⅱ","website":"www.hualanbio.com","mainBusiness":"血液制品、疫苗、基因工程产品研发、生产和销售。","productsName":["人血白蛋白","静注人免疫球蛋白","人免疫球蛋白","人凝血酶原复合物","人凝血因子VIII","狂犬病人免疫球蛋白","乙型肝炎人免疫球蛋白","破伤风人免疫球蛋白","人纤维蛋白原","人纤维蛋白胶","外用冻干人凝血酶","流感病毒裂解疫苗","甲型H1N1流感病毒裂解疫苗","ACYW135群脑膜炎球菌多糖疫苗","重组乙型肝炎疫苗(汉逊酵母)","A群C群脑膜炎球菌多糖疫苗","四价流感病毒裂解疫苗"],"actualController":"安康","actualControllerSharePercentage":"45.21%","registeredCapital":"18.24亿元","employeeAmount":"2417","phone":"86-0373-3559989","location":"河南省新乡市牧野区华兰大道甲1号","chineseDescription":"华兰生物工程股份有限公司是一家主要从事血液制品、菌疫苗的生产和销售的公司.公司的主要产品包括人血白蛋白、静注人免疫球蛋白(PH4)、人凝血酶原复合物、人凝血因子Ⅷ等.公司目前生产规模、市场占有率均居行业前列,成为血液制品、疫苗产品行业的龙头企业.1998年公司是首家通过了血液制品行业的GMP认证,为国家定点大型生物制品生产企业,在全国同行业企业中处于领先地位.公司先后承担多项国家、省、市级科技攻关项目,其中外科用冻干人纤维蛋白胶被列入国家863项目.公司在2009 年发生的甲型H1N1 流感疫情中依靠公司的科研实力在全球率先研制出甲型H1N1 流感疫苗,公司甲流疫苗临床研究报告刊登于世界顶尖医...查看全部▼华兰生物工程股份有限公司是一家主要从事血液制品、菌疫苗的生产和销售的公司.公司的主要产品包括人血白蛋白、静注人免疫球蛋白(PH4)、人凝血酶原复合物、人凝血因子Ⅷ等.公司目前生产规模、市场占有率均居行业前列,成为血液制品、疫苗产品行业的龙头企业.1998年公司是首家通过了血液制品行业的GMP认证,为国家定点大型生物制品生产企业,在全国同行业企业中处于领先地位.公司先后承担多项国家、省、市级科技攻关项目,其中外科用冻干人纤维蛋白胶被列入国家863项目.公司在2009 年发生的甲型H1N1 流感疫情中依靠公司的科研实力在全球率先研制出甲型H1N1 流感疫苗,公司甲流疫苗临床研究报告刊登于世界顶尖医学杂志《新英格兰医学杂志》,标志着中国疫苗得到了世界的认可,开创了中国疫苗的先河。收起▲","foundedDate":"1992-03-20","goPublicDate":"2004-06-25","companyHistory":"华兰生物工程股份有限公司（以下简称“本公司”或“公司”）是经中华人民共和国对外贸易经济合作部[2000]外经贸资二函字第658号文件及河南省人民政府豫股批字[2000]第40号文件批准，由华兰生物工程有限公司以2000年8月31日经审计的净资产4,500万元为基数按1:1的比例进行折股，整体变更成立的股份有限公司。2004年经中国证券监督管理委员会（以下简称“中国证监会”）证监发行字[2004]68号核准于2004年6月10日向社会公开发行2,200万股人民币普通股，并于2004年6月25日在深圳证券交易所上市交易。\n    经过历年的派送红股、转增股本及增发新股,截止2019年6月30日,本公司累计发行股本总数140,305.902万股,注册资本为140,305.902万元。\n　　截止2019年12月31日，本公司累计发行股本总数140,305.902万股，注册资本为140,305.902万元。公司注册地址：新乡市华兰大道甲1号；公司的统一社会信用代码：91410000614914114G；公司法定代表人：安康；本公司最终实际控制人为安康。收起▲","shareholders":[{"organizationId":"","holderName":"安康","totalShare":"2.51亿","sharePercentage":"17.86%"},{"organizationId":"03143572","holderName":"重庆市晟康生物科技开发有限公司","totalShare":"2.11亿","sharePercentage":"15.05%"},{"organizationId":"00204945","holderName":"香港科康有限公司","totalShare":"1.85亿","sharePercentage":"13.15%"},{"organizationId":"","holderName":"新疆晟康新开企业管理顾问有限合伙企业","totalShare":"5099.43万","sharePercentage":"3.63%"},{"organizationId":"T000125370","holderName":"香港中央结算有限公司","totalShare":"4678.95万","sharePercentage":"3.33%"},{"organizationId":"","holderName":"中国银行股份有限公司-易方达中小盘混合型证券投资基金","totalShare":"4600.00万","sharePercentage":"3.28%"},{"organizationId":"T000073058","holderName":"中国证券金融股份有限公司","totalShare":"4171.52万","sharePercentage":"2.97%"},{"organizationId":"","holderName":"中国建设银行股份有限公司-易方达新丝路灵活配置混合型证券投资基金","totalShare":"1800.00万","sharePercentage":"1.28%"},{"organizationId":"T000280241","holderName":"中央汇金资产管理有限责任公司","totalShare":"1601.93万","sharePercentage":"1.14%"},{"organizationId":"","holderName":"交通银行-易方达50指数证券投资基金","totalShare":"1556.30万","sharePercentage":"1.11%"}],"englishDescription":"HUALAN BIOLOGICAL ENGINEERING, INC. is a China-based company principally engaged in the research, development, production and sales of blood products. It also produces vaccine products and biological engineering products. The Company's main products include human albumins, human immunoglobulin for intravenous injection, human immunoglobulin, human coagulation factors, human rabies immunoglobulin, human tetanus immunoglobulin and influenza vaccines, among others. The Company mainly operates its businesses in domestic markets.","englishIndustry":"Biotechnology & Drugs","Price to earnings (ttm)":"93.17","Price to sales (ttm)":"32.17","Price to book (mrq)":"17.43","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"0.74","Lt debt to equity (mrq)":"0.00","Return on investment (ttm)":"21.46","Return on equity (ttm)":"18.76","Income statement":{"Revenue":"3,699.94","Total revenue":"3,699.94","Cost of revenue, total":"1,346.17","Gross profit":"2,353.77","Selling/general/admin. expenses, total":"704.84","Research & development":"127.38","Depreciation/amortization":"87.19","Interest exp.(inc.),net-operating, total":"(167.49)","Unusual expense (income)":"1.68","Other operating expenses, total":"(13.36)","Total operating expense":"2,086.42","Operating income":"1,613.53","Other, net":"(3.29)","Net income before taxes":"1,610.24","Provision for income taxes":"231.36","Net income after taxes":"1,378.88","Minority interest":"(95.43)","Net income before extra. items":"1,283.45","Net income":"1,283.45","Income available to com excl extraord":"1,283.45","Income available to com incl extraord":"1,283.45","Diluted net income":"1,283.45","Diluted weighted average shares":"1,823.98","Diluted eps excluding extraord items":"0.70","Dps - common stock primary issue":"0.31","Diluted normalized eps":"0.70","Gain (loss) on sale of assets":"(0.61)","Dilution adjustment":"0.00"},"Balance sheet":{"Cash":"3.07","Cash & equivalents":"599.03","Short term investments":"2,307.41","Cash and short term investments":"2,909.51","Accounts receivable - trade, net":"964.63","Total receivables, net":"1,134.52","Total inventory":"1,159.57","Prepaid expenses":"19.85","Other current assets, total":"461.43","Total current assets":"5,684.88","Property/plant/equipment, total - gross":"2,627.17","Accumulated depreciation, total":"(1,178.09)","Property/plant/equipment, total - net":"1,449.08","Goodwill, net":"1.10","Intangibles, net":"215.55","Long term investments":"105.13","Other long term assets, total":"127.45","Total assets":"7,583.20","Accounts payable":"64.60","Accrued expenses":"12.81","Notes payable/short term debt":"0.00","Other current liabilities, total":"617.06","Total current liabilities":"694.48","Long term debt":"0.00","Total long term debt":"0.00","Total debt":"0.00","Deferred income tax":"4.78","Minority interest":"340.81","Total liabilities":"1,040.07","Common stock, total":"1,403.06","Additional paid-in capital":"495.87","Retained earnings (accumulated deficit)":"4,644.20","Total equity":"6,543.13","Total liabilities & shareholders' equity":"7,583.20","Total common shares outstanding":"1,823.98","Tangible book value per share, common eq":"3.47"},"Cash flow":{"Cash receipts":"3,620.82","Cash payments":"(920.15)","Cash taxes paid":"(417.61)","Changes in working capital":"(920.30)","Cash from operating activities":"1,362.76","Capital expenditures":"(272.95)","Other investing cash flow items, total":"(572.01)","Cash from investing activities":"(844.97)","Financing cash flow items":"49.89","Total cash dividends paid":"(390.65)","Cash from financing activities":"(340.76)","Foreign exchange effects":"(0.00)","Net change in cash":"177.03","Issuance (retirement) of debt, net":"(150.00)"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"64.93","52 Week High":"65.60","52 Week Low":"22.09","Pricing date":"","10 Day Average Trading Volume":"47.55","Market Capitalization":"118,456.10","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"754.29","Beta":"0.68","1 Day Price Change":"6.48","13 Week Price Return (Daily)":"67.04","26 Week Price Return (Daily)":"133.88","5 Day Price Return (Daily)":"20.51","52 Week Price Return (Daily)":"187.20","Year To Date Price Return (Daily)":"140.14","Month to Date Price Return (Daily)":"29.57","Price Relative to S&P500 (4 Week)":"24.94","Price Relative to S&P500 (13 Week)":"31.33","Price Relative to S&P500 (26 Week)":"83.19","Price Relative to S&P500 (52 Week)":"95.18","Price Relative to S&P500 (YTD)":"83.67"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"0.70","EPS excl. Extra Items (TTM)":"0.70","EPS Normalized (Annual)":"0.70","Revenue per Share (Annual)":"2.03","Revenue per Share (TTM)":"2.02","Book Value (Per Share Annual)":"3.59","Book Value (Per Share Quarterly)":"3.72","Tangible Book Value (Per Share Annual)":"3.47","Tangible Book Value (Per Share Quarterly)":"3.61","Cash Per Share (Per Share Annual)":"1.60","Cash Per Share (Per Share Quarterly)":"1.88","Cash Flow (Per Share Annual)":"0.84","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.31","Dividends (Per Share TTM)":"0.31","EBITD (Per Share TTM)":"0.79","EPS Basic excl. Extra Items (Annual)":"0.70","EPS Basic excl. Extra Items (TTM)":"0.70","EPS incl. Extra Items (Annual)":"0.70","EPS incl. Extra Items (TTM)":"0.70","Free Cash Flow (Per Share TTM)":"0.31","Dividend (Per Share 5Y)":"0.20"},"Valuation":{"P/E excl. Extra Items (Annual)":"92.28","P/E excl. Extra Items (TTM)":"93.17","P/E Normalized (Annual)":"92.17","Price to sales (Annual)":"32.02","Price to sales (TTM)":"32.17","Price to Tangible Book (Annual)":"18.72","Price to Tangible Book (Quarterly)":"18.01","Price to Free Cash Flow (Per Share Annual)":"169.43","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"210.34","Price to Book (Annual)":"18.10","Price to Book (Quarterly)":"17.43","P/E Basic excl. Extra Items (TTM)":"52.89","P/E excl. Extra Items High (TTM)":"52.89","P/E excl. Extra Items Low (TTM)":"26.77","P/E incl. Extra Items (TTM)":"93.17","Net Debt (Interim)":"-3,379.77","Net Debt (Annual)":"-2,909.51","Dividend Yield (5Y)":"1.11","Dividend Yield":"0.47","Current Dividend Yield (TTM)":"0.47"},"Financial Strength":{"Free Cash Flow (Annual)":"699.16","Current Ratio (Annual)":"8.19","Net Interest coverage (Annual)":"--","Long Term Debt/Equity (Annual)":"0.00","Payout Ratio (Annual)":"43.74","Quick Ratio (Annual)":"6.52","Total Debt/Total Equity (Annual)":"0.00","Current EV/Free Cash Flow (Annual)":"132.26","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"8.84","Long Term Debt/Equity (Quarterly)":"0.00","Quick Ratio (Quarterly)":"7.11","Total Debt/Total Equity (Quarterly)":"0.74","Free Cash Flow (TTM)":"563.18","Net Interest Coverage (TTM)":"--","Payout Ratio (TTM)":"44.16"},"Margins":{"Gross Margin (Annual)":"63.62","Gross Margin (TTM)":"63.16","Net Profit Margin % (Annual)":"37.27","Net Profit Margin (TTM)":"36.99","Operating Margin (Annual)":"43.61","Operating Margin (TTM)":"43.46","Pretax Margin (TTM)":"43.26","Pretax Margin (Annual)":"43.52","Operating Margin (5Y)":"42.76","Pretax Margin (5Y)":"43.50","Free Operating Cash Flow/Revenue (5Y)":"8.29","Free Operating Cash Flow/Revenue (TTM)":"15.30","Gross Margin (5Y)":"62.08","Net Profit Margin (5Y)":"37.39"},"Management Effectiveness":{"Return on Assets (Annual)":"19.59","Return on Equity (TTM)":"18.76","Return on Average Equity (Annual)":"21.27","Return on Average equity (TTM)":"20.04","Return on Investment (Annual)":"22.84","Return on Investment (TTM)":"21.46","Return on Average Assets (5Y)":"18.21","Return on Average Equity (5Y)":"20.02","Return on Investment (5Y)":"20.59","Asset Turnover (Annual)":"0.53","Asset Turnover (TTM)":"0.51","Inventory Turnover (Annual)":"1.14","Inventory Turnover (TTM)":"1.10","Net Income/Employee (Annual)":"604,637.90","Net Income/Employee (TTM)":"563,383.10","Receivables Turnover (Annual)":"3.95","Receivables Turnover (TTM)":"3.77","Revenue/Employee (Annual)":"1,622,426.00","Revenue/Employee (TTM)":"1,523,251.00"},"Growth":{"Revenue Growth (Quarterly YoY)":"-2.62","Revenue Growth Rate (5Y)":"24.37","EPS Growth (Quarterly YoY)":"-4.76","EPS Growth (TTM YoY)":"6.19","EPS Growth Rate (5Y)":"18.83","Dividend Growth Rate (3Y)":"14.47","Revenue Growth (TTM YoY)":"9.88","Revenue Growth (Per Share 5Y)":"24.22","Revenue Growth Rate (3Y)":"24.13","EPS Growth Rate (3Y)":"17.82","Book Value Growth Rate (Per Share 5Y)":"13.84","Tangible Book Value Total Equity CAGR (5Y)":"14.63","Capital Spending growth rate 5 year":"14.42","EBITDA CAGR (5Y)":"20.95","EBITDA Interim CAGR (5Y)":"24.03","Free Operating Cash Flow CAGR (5Y)":"41.84","Total Debt CAGR (5Y)":"--","Net Profit Margin Growth Rate (5Y)":"-2.96"},"Income Statement":{"Revenue (Annual)":"3,699.94","Revenue (TTM)":"3,681.70","EBITD (Annual)":"1,608.62","EBITD (TTM)":"1,444.51","Earnings Before Taxes (Annual)":"1,610.24","Earnings Before Taxes (TTM)":"1,592.82","Net Income to Common (Annual)":"1,283.45","Net Income to Common (TTM)":"1,271.23","Earnings Before Taxes Normalized (Annual)":"1,611.92","Net Income Available to Common Normalized (Annual)":"1,284.89","Diluted Normalized EPS excl. Extra Items (TTM)":"0.70"}}}